Regeneron Recognized in BioSpace 2027 Best Places to Work List
Regeneron was named among the top 20 large employers in the life sciences industry in BioSpace's 2027 Best Places to Work rankings.
Stocks · News reference
Analyst Maintains Buy Rating on Regeneron Pharmaceuticals
Analyst Tazeen Ahmad has maintained a 'Buy' rating and a $1,030 price target for Regeneron Pharmaceuticals, Inc.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients
Soleo Health Named Specialty Pharmacy Partner for Regeneron's Pasatru™
Soleo Health has been selected as a specialty pharmacy partner to support the distribution and patient access for Regeneron's FDA-approved treatment, Pasatru™ (garetosmab-grts).
Soleo Health Selected as a Specialty Pharmacy Partner for Pasatru™, a New Treatment in Adults with Fibrodysplasia Ossificans Progressiva
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's newly FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP). The company will provide patient access support, infusion services, and clinical coordination through its SoleoRare® division, leveraging its expertise in ultra-rare diseases.
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.